New virginiamycin M1 derivatives: synthesis, cholecystokinin binding inhibitory and antimicrobial properties.
Lam
Y K
YK
Merck Research Laboratories, Rahway, New Jersey 07065.
Dai
P
P
Zink
D L
DL
Smith
A J
AJ
Lee
N W
NW
Freedman
S
S
Salvatore
M J
MJ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006168:Guinea Pigs; D006801:Humans; D008826:Microbial Sensitivity Tests; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000187:drug effects / Q000378:metabolism; D014769:Virginiamycin / Q000031:analogs & derivatives* / Q000138:chemical synthesis*
D000900:Anti-Bacterial Agents; D011949:Receptors, Cholecystokinin; D014769:Virginiamycin; D002766:Cholecystokinin